


Global spotlight 21.2: Key additions for the first half of September 2022



There is one newly added evidence synthesis and eight updates to living evidence syntheses already included in the public-health measures parts of the COVID-END inventory of ‘best’ evidence syntheses,* and 13 newly added evidence syntheses and 12 updates to living evidence syntheses already included in the clinical management parts of the inventory.

**COVID-END assigns ‘best’ status to evidence syntheses based on an assessment of how up-to-date they are (i.e., the date of the last search, with priority given to living reviews), quality (using the AMSTAR tool), and whether there is an evidence profile available (e.g., GRADE).*

Taxonomy section	Title	Type of synthesis	Criteria for best evidence synthesis		
			Date of last search	Quality (AMSTAR) rating	Evidence profile (e.g., GRADE) available
Public-health measures	SARS-CoV-2 RNA presence in the air was largely found in indoor environments, as opposed to outdoor areas; among the indoor environments, hospitals reported a higher viral presence compared to other indoor environments [Review of studies of unknown quality]	Newly added full review	2021-08-31	4/10	No
Public-health measures	[Janssen vaccine] Vaccination with the Janssen vaccine reduces the risk of contracting COVID-19 and moderate to severe COVID-19 infection; it probably does not increase the risk of serious adverse events	Update to living review	2022-09-27	7/11	Yes
Public-health measures	[Sinopharm - WIBP] Vaccination with Sinopharm vaccine probably results in little or no difference in the risk of getting COVID-19 (severe or any) infection; it probably increases the risk of any adverse event	Update to living review	2022-09-27	6/9	Yes
Public-health measures	Evidence suggests insufficient protection against COVID-19 infection produced by the Omicron variant of concern immediately after receiving a booster dose with no decrease in vaccine effectiveness up to 20 weeks, while vaccine effectiveness against hospitalization was reported after 12 weeks of receiving a booster shot	Update to living rapid review	2022-09-14	8/9	No
Public-health measures	[BioNTech/Pfizer against variants of concern] One dose of BNT162b2 [Pfizer] vaccine may not reach the threshold for protection against infection (including symptomatic and severe infection) from the Omicron variant of concern (including the BA.2 subvariant) in children aged 3 to 11 years and adolescents aged 12 to 17 years (other variants are also included in the report)	Update to living rapid review	2022-09-13	8/9	Yes
Public-health measures	[BioNTech/Pfizer against variants of concern] Two doses of BNT162b2 [Pfizer] vaccine may not reach the threshold for protection against infection (including symptomatic infection) from the Omicron variant of concern in children aged 5 to 11 years and they probably may not reach the threshold for protection for infection (including symptomatic and severe infection) from the	Update to living rapid review	2022-09-13	8/9	Yes

	Omicron variant of concern (including the BA.2 subvariant) in adolescents aged 12 to 17 years; they may prevent MIS-C produced by the Omicron variant of concern (other variants are also included in the report)				
Public-health measures	[BioNTech/Pfizer against variants of concern] Three doses of BNT162b2 [Pfizer] vaccine may not reach the threshold for protection against infection (including severe infection) from the Omicron variant of concern in adolescents aged 12 to 17 years, while they probably do not reach the threshold for protection against symptomatic infection in adolescents aged 12 to 17 years; they may provide some protection against infection from the BA.2 subvariant (other variants are also included in the report)	Update to living rapid review	2022-09-13	8/9	Yes
Public-health measures	[CoronaVac/Sinovac vaccine against variants of concern] One dose of Coronavac/Sinovac vaccine may not reach the threshold for protection against infection and ICU admission against the Omicron variant of concern (including the BA.2 subvariant) in children aged 3 to 11 years and adolescents aged 12 to 18 years, while it may not reach the threshold for protection against symptomatic infection from the Omicron variant of concern in children aged 6 to 11 years (other variants are also included in the report)	Update to living rapid review	2022-09-13	8/9	Yes
Public-health measures	[Moderna vaccine against variants of concern] Two doses of Moderna [mRNA-1723] vaccine may not reach the threshold for protection against infection from the Omicron variant of concern in adolescents aged 12 to 17 years	Update to living rapid review	2022-09-13	8/9	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Curcumin + piperine] The effects of using curcumin + piperine to treat COVID-19 patients are currently uncertain	Newly added living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Curcumin + quercetin + vitamin D] The effects of using curcumin + quercetin + vitamin D to treat COVID-19 patients are currently uncertain	Newly added living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Edaravone] The effects of using edaravone to treat COVID-19 patients are currently uncertain	Newly added living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Ensovibep] The effects of using ensovibep to treat COVID-19 patients are currently uncertain	Newly added living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Ethanol (inhaled)] The effects of using inhaled ethanol to treat COVID-19 patients are currently uncertain	Newly added living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Fenofibrate] The benefits of using fenofibrate to treat COVID-19 patients are currently uncertain; it may not increase severe adverse events	Newly added living rapid review	2022-08-29	7/11	Yes

Clinical management of COVID-19 and pandemic-related health issues	[Gabapentin + montelukast] The effects of using gabapentin + montelukast to treat COVID-19 patients are currently uncertain	Newly added living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[hzVSF-v13] The effects of hzVSF-v13 to treat COVID-19 patients are currently uncertain	Newly added living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Lithium] The effects of using lithium to treat COVID-19 patients are currently uncertain	Newly added living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Nicotine patches] The effects of using nicotine patches to treat COVID-19 patients are currently uncertain	Newly added living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Norelgestromin + ethinylestradiol] The effects of norelgestromin + ethinylestradiol to treat COVID-19 patients are currently uncertain	Newly added living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[OP-101] The effects of using OP-101 to treat COVID-19 patients are currently uncertain	Newly added living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Tafenoquine] The effects of using tafenoquine to treat COVID-19 are currently uncertain	Newly added living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Baricitinib] Among hospitalized COVID-19 patients, using baricitinib may reduce mortality and disease progression, while it slightly increases clinical improvement; it may not increase serious adverse events	Update to living review	2022-09-23	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Molnupiravir] In COVID-19 outpatients, molnupiravir probably slightly reduces mortality and hospitalization or death, while it may increase clinical improvement; it probably does not increase serious adverse events	Update to living review	2022-09-23	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	In hospitalized patients, adding convalescent plasma to standard care probably does not have an effect on mortality at 28 days and disease progression, while it does not have an effect on clinical improvement, and it may slightly increase serious adverse events; in outpatients, convalescent plasma may make little or no difference in mortality and disease progression, it probably slightly reduces hospitalization or death and it may not increase serious adverse events	Update to living review	2022-09-09	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Anakinra] Using anakinra to treat COVID-19 patients may not reduce mortality and it may not increase severe adverse events	Update to living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Cilgavimab + tixagevimab] Using cilgavimab + tixagevimab to treat COVID-19 patients probably reduces mortality and hospitalizations	Update to living rapid review	2022-08-29	10/11	Yes

Clinical management of COVID-19 and pandemic-related health issues	[Corticosteroids] Low- or moderate-dose treatment with corticosteroids probably reduces mortality in severe COVID-19 patients, while higher-doses may not be more effective than standard dose schemes	Update to living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Emtricitabine/tenofovir] Using emtricitabine/tenofovir to treat COVID-19 patients may not reduce mortality and it may decrease mechanical ventilation; its effects on other outcomes are uncertain	Update to living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Favipiravir] Using favipiravir may not reduce hospitalizations and it probably does not have an effect on time to symptom resolution among COVID-19 patients; it may increase mortality and mechanical ventilation	Update to living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Inhaled corticosteroids] Using inhaled corticosteroids may improve time to symptom resolution, but they probably do not have an important effect on hospitalizations; but their effects on other outcomes are uncertain	Update to living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Ivermectin] Ivermectin probably does not have an effect on mortality, time to symptom resolution, and hospitalizations	Update to living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Opaganib] Using opaganib to treat COVID-19 patients may not reduce mortality and mechanical ventilation, while it may increase symptom resolution and improvement; it may not increase severe adverse events	Update to living rapid review	2022-08-29	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	[Vitamin D] Using vitamin D to treat COVID-19 patients may reduce hospitalizations, while its effects on other outcomes are uncertain	Update to living rapid review	2022-08-29	7/11	Yes